Abstract
Purpose
Peroxiredoxins, which reduced intracellular peroxides as a noval kind of antioxidant protein, were extensively expressed in various types of cancers and were thought as a biomarker of cancer cells. In this work, we performed genotyping analyses for tag SNP of Prdx 1, 2 and 6, and then evaluated the association with susceptibility and clinic stage of esophageal squamous cell carcinoma (ESCC) in a case–control study.
Methods
The protein level of these Prdx isoforms in ESCC cancer samples was evaluated by Western blot. Then 356 ESCC cancer cases and 315 controls were genotyped by SNPshot assay. Differences in frequencies of the genotypes of the SNPs variant between the cases and controls were evaluated by using the chi-square test.
Results
Our result of Western blot confirmed the aberrant expression of Prdx 1, 2 and 6 in ESCC samples, which was coincident with other studies. After genotyping by SNPshot assay, the result showed that the allele and genotype frequencies did not differ between the patients and controls. And no association between the polymorphism and the progression of ESCC including tumor grade and stage was found.
Conclusions
Our data suggested that polymorphisms of Prdx 1, 2 and 6 were not associated with esophageal cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen MF, Lee KD, Yeh CH, Chen WC, Huang WS, Chin CC, Lin PY, Wang JY (2010) Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78:868–878
Haubold B, Wiehe T (2003) Calculating the SNP-effective sample size from an alignment. Bioinformatics 18:36–38
Ho JN, Lee SB, Lee SS, Yoon SH, Kang GY, Hwang SG, Um HD (2010) Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol Cancer Ther 9:825–832
Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, Sakata H, Matsushita K, Ochiai T (2007) Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep 18:867–871
Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH (2005) 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 11:571–578
Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, Yoon K, Jung M, Choe W (2009) Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 21:1391–1396
Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ (2006) Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 24:4347–4355
Lee W, Choi KS, Riddell J, Ip C, Ghosh D, Park JH, Park YM (2007) Human peroxiredoxin 1 and 2 are not duplicate proteins: the unique presence of CYS83 in Prx1 underscores the structural and functional differences between Prx1 and Prx2. J Biol Chem 282:22011–22222
Li Y, Li X, Shi L, Yang M, Yang Y, Tao W, Shi L, Xiong Y, Zhang Y, Yao Y (2011) Association of adiponectin SNP+45 and SNP+276 with type 2 diabetes in Han Chinese populations: a meta-analysis of 26 case-control studies. PLoS One 6:e19686
Neumann CA, Fang Q (2007) Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7:375–380
Pati N, Schowinsky V, Kokanovic O, Magnuson V, Ghosh S (2004) A comparison between SNaPshot, pyrosequencing, and biplex invader SNP genotyping methods: accuracy, cost, and throughput. J Biochem Biophys Methods 60:1–12
Rushefski M, Aplenc R, Meyer N, Li M, Feng R, Lanken PN, Gallop R, Bellamy S, Localio AR, Feinstein SI, Fisher AB, Albelda SM, Christie JD (2011) Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma. BMC Med Genet 12:77
Schläwicke Engström K, Nermell B, Concha G, Strömberg U, Vahter M, Broberg K (2009) Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat Res 667:4–14
Schuchert MJ, Luketich JD, Landreneau RJ (2010) Management of esophageal cancer. Curr Probl Surg 47:845–946
Wang K, Guo H, Hu H, Xiong G, Guan X, Li J, Xu X, Yang K, Bai Y (2010a) A functional variation in pre-microRNA-196a is associated with susceptibility of esophageal squamous cell carcinoma risk in Chinese Han. Biomarkers 15:614–618
Wang W, Gou L, Xie G, Tong A, He F, Lu Z, Yao Y, Liu K, Li J, Tang M, Chen L, Yang J, Hu H, Wei YQ (2010b) Proteomic analysis of interstitial fluid in bone marrow identified that peroxiredoxin 2 regulates H(2)O(2) level of bone marrow during aging. J Proteome Res 9:3812–3819
Wei HB, Lu XS, Shang LH, Xu G, Hu J, Che DH, Liu F, Wu Y, Zhang GM, Yu Y (2011) Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res 42:412–420
Woo HA, Yim SH, Shin DH, Kang D, Yu DY, Rhee SG (2010) Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell 140:517–528
Xiong G, Guo H, Wang K, Hu H, Wang D, Xu X, Guan X, Yang K, Bai Y (2010) Polymorphisms of decoy receptor 3 are associated with risk of esophageal squamous cell carcinoma in Chinese Han. Tumour Biol 31:443–449
Yang CS (1980) Research on esophageal cancer in China: a review. Cancer Res 40:2633–2644
Zhang B, Wang Y, Su Y (2009a) Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286:154–160
Zhang XZ, Xiao ZF, Li C, Xiao ZQ, Yang F, Li DJ, Li MY, Li F, Chen ZC (2009b) Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. Cancer Sci 100:2396–2401
Ziech D, Franco R, Pappa A, Panayiotidis MI (2011) Reactive oxygen species (ROS)—induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res 711:167–173
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (No. 30772146).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, B., Wang, K., He, G. et al. Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer. J Cancer Res Clin Oncol 138, 621–626 (2012). https://doi.org/10.1007/s00432-011-1119-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-011-1119-5